Literature DB >> 29559742

Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast.

Michael S Toss1,2, I Miligy1,3, Abdubaqi Al-Kawaz1, Mansour Alsleem1, Hazem Khout1,4, Padmashree C Rida5, Ritu Aneja5, Andrew R Green1, Ian O Ellis1,4, Emad A Rakha6,7,8.   

Abstract

Tumor-infiltrating lymphocytes (TILs) provide prognostic value in invasive breast cancer and guidelines for their assessment have been published. This study aims to evaluate: (a) methods of TILs assessment, and (b) their prognostic significance in breast ductal carcinoma in situ (DCIS). Hematoxylin and eosin sections from two clinically annotated DCIS cohorts; a training set (n = 150 pure DCIS) and a validation set (n = 666 comprising 534 pure DCIS and 132 cases wherein DCIS and invasive breast carcinoma were co-existent) were assessed. Seven different scoring methods were applied to the training set to identify the most optimal reproducible method associated with strongest prognostic value. Among different methods, TILs touching ducts' basement membrane or away from it by one lymphocyte cell thickness provided the strongest significant association with outcome and highest concordance rate [inter-cluster correlation coefficient = 0.95]. Assessment of periductal TILs at increasing distances from DCIS (0.2 , 0.5 , and 1 mm) as well as percent of stromal TILs were practically challenging and showed lower concordance rates than touching TILs. TILs hotspots and lymphoid follicles did not show prognostic significance. Within the pure DCIS validation set, dense TILs were associated with younger age, symptomatic presentation, larger size, higher nuclear grade, comedo necrosis and estrogen receptor negativity as well as shorter recurrence-free interval (p = 0.002). In multivariate survival analysis, dense TILs were independent predictor of shorter recurrence-free interval (p = 0.002) in patients treated with breast conservation. DCIS associated with invasive carcinoma showed denser TILs than pure DCIS (p = 9.0 × 10-13). Dense TILs is an independent prognostic variable in DCIS. Touching TILs provides a reproducible method for their assessment that can potentially be used to guide management.

Entities:  

Mesh:

Year:  2018        PMID: 29559742     DOI: 10.1038/s41379-018-0040-8

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  21 in total

1.  Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study.

Authors:  Serdar Altinay; Laurent Arnould; Noella Bletard; Cecile Colpaert; Franceska Dedeurwaerdere; Benjamin Dessauvagie; Valérie Duwel; Giuseppe Floris; Stephen Fox; Clara Gerosa; Shabnam Jaffer; Eline Kurpershoek; Magali Lacroix-Triki; Andoni Laka; Kathleen Lambein; Gaëtan Marie MacGrogan; Caterina Marchió; Dolores Martin Martinez; Sharon Nofech-Mozes; Dieter Peeters; Alberto Ravarino; Emily Reisenbichler; Erika Resetkova; Souzan Sanati; Anne-Marie Schelfhout; Vera Schelfhout; Abeer M Shaaban; Renata Sinke; Claudia Maria Stanciu-Pop; Claudia Stobbe; Carolien H M van Deurzen; Koen Van de Vijver; Anne-Sophie Van Rompuy; Stephanie Verschuere; Anne Vincent-Salomon; Hannah Wen; Hélène Dano; Caroline Bouzin; Christine Galant; Mieke R Van Bockstal
Journal:  Mod Pathol       Date:  2019-09-18       Impact factor: 7.842

Review 2.  Ductal carcinoma in situ of breast: update 2019.

Authors:  Sunil S Badve; Yesim Gökmen-Polar
Journal:  Pathology       Date:  2019-08-28       Impact factor: 5.306

3.  A Quantitative Centrosomal Amplification Score Predicts Local Recurrence of Ductal Carcinoma In Situ.

Authors:  Michael S Toss; Guanhao Wei; Jaspreet Kaur; Karuna Mittal; Da Hoon Choi; Brian D Melton; Remus M Osan; Islam M Miligy; Andrew R Green; Emiel A M Janssen; Håvard Søiland; Keerthi Gogineni; Upender Manne; Padmashree Rida; Emad A Rakha; Ritu Aneja
Journal:  Clin Cancer Res       Date:  2020-01-14       Impact factor: 12.531

4.  Prognostic Role of Lymphocyte-C-Reactive Protein Ratio in Colorectal Cancer: A Systematic Review and Meta Analysis.

Authors:  Xinglong He; Ade Su; Yongcheng Xu; Diaolong Ma; Guoyuan Yang; Yiyun Peng; Jin Guo; Ming Hu; Yuntao Ma
Journal:  Front Oncol       Date:  2022-07-06       Impact factor: 5.738

Review 5.  Ductal Carcinoma in Situ: Molecular Changes Accompanying Disease Progression.

Authors:  Gemma M Wilson; Phuong Dinh; Nirmala Pathmanathan; J Dinny Graham
Journal:  J Mammary Gland Biol Neoplasia       Date:  2022-05-14       Impact factor: 2.698

Review 6.  Learning to distinguish progressive and non-progressive ductal carcinoma in situ.

Authors:  Anna K Casasent; Mathilde M Almekinders; Charlotta Mulder; Proteeti Bhattacharjee; Deborah Collyar; Alastair M Thompson; Jos Jonkers; Esther H Lips; Jacco van Rheenen; E Shelley Hwang; Serena Nik-Zainal; Nicholas E Navin; Jelle Wesseling
Journal:  Nat Rev Cancer       Date:  2022-10-19       Impact factor: 69.800

7.  Ductal carcinoma in situ of the breast: immune cell composition according to subtype.

Authors:  Marie Colombe Agahozo; Mieke R van Bockstal; Floris H Groenendijk; Thierry P P van den Bosch; Pieter J Westenend; Carolien H M van Deurzen
Journal:  Mod Pathol       Date:  2019-08-02       Impact factor: 7.842

8.  Deep-Learning-Based Characterization of Tumor-Infiltrating Lymphocytes in Breast Cancers From Histopathology Images and Multiomics Data.

Authors:  Zixiao Lu; Siwen Xu; Wei Shao; Yi Wu; Jie Zhang; Zhi Han; Qianjin Feng; Kun Huang
Journal:  JCO Clin Cancer Inform       Date:  2020-05

9.  Immune-infiltration based signature as a novel prognostic biomarker in gastrointestinal stromal tumour.

Authors:  Zhe-Wei Wei; Jing Wu; Wei-Bin Huang; Jin Li; Xiao-Fang Lu; Yu-Jie Yuan; Wen-Jun Xiong; Xin-Hua Zhang; Wei Wang; Yu-Long He; Chang-Hua Zhang
Journal:  EBioMedicine       Date:  2020-06-20       Impact factor: 8.143

Review 10.  Low lymphocyte count and high monocyte count predicts poor prognosis of gastric cancer.

Authors:  Fan Feng; Gaozan Zheng; Qiao Wang; Shushang Liu; Zhen Liu; Guanghui Xu; Fei Wang; Man Guo; Xiao Lian; Hongwei Zhang
Journal:  BMC Gastroenterol       Date:  2018-10-11       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.